Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
- Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®*
- Hyrimoz® HCF to launch progressively across Europe
- Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in Europe
Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today.
Hyrimoz® HCF, like the currently available 50mg/mL version of Hyrimoz®, is indicated for all conditions covered by the reference medicine*: rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.1
Rebecca Guntern, President Europe Sandoz said: “People living with chronic inflammatory conditions can experience debilitating effects on daily life. The launch of Hyrimoz® HCF in Europe is a key milestone in offering an additional treatment option to those that need it and showcases our unwavering commitment to expanding access to high-quality medicines.”
Hyrimoz® citrate-free HCF is an updated formulation (100 mg/mL) to the currently available Hyrimoz® 50 mg/mL and offers a 50 percent reduction in injection volume, thereby potentially decreasing the number of injections required for patients who need 80 mg/mL or higher dosing. The HCF formulation is administered with the familiar Hyrimoz® SensoReady® pen, aiming for an enhanced yet familiar patient experience.
The launch of Hyrimoz ® HCF strengthens the Sandoz biosimilar portfolio in immunology, including Erelzi® (biosimilar etanercept), Zessly® (biosimilar infliximab) and Rixathon® (biosimilar rituximab, including rheumatoid arthritis indication). Hyrimoz® citrate-free HCF (adalimumab-adaz) launched in the US in July 2023.
Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably across a range of areas including immunology, oncology, supportive care, and endocrinology. It has a leading global portfolio with eight marketed biosimilars and a further 25 assets in various stages of development. Since launching the first biosimilar in Europe in 2006, Sandoz has helped to create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels further innovation.
Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). The adalimumab reference medicine (Humira®*) was first approved with an adalimumab concentration of 50 mg/mL.1 In 2015, the EMA and US FDA approved Humira® HCF, which contains adalimumab at a concentration of 100 mg/mL.
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
- EMA. Humira® EPAR Product Information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira. [Accessed October 2023]
*Humira® is a registered trademark of AbbVie Biotechnology Ltd
# # #
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 500 million patients worldwide, generating substantial global healthcare savings and an even larger total social impact. Its leading portfolio of more than 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2022, Sandoz achieved sales of USD 9.1 billion and core EBITDA of USD 1.9 billion.
|Global Media Relations contacts||Investor Relations contacts|
| Joerg E. Allgaeuer|
+49 171 838 4838
| Karen M. King|
+1 609 722 0982
| Chris Lewis|
+49 174 244 9501
| Laurent de Weck|
+41 79 795 7364
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Company Announcement 5/20236.12.2023 14:51:46 CET | Press release
NOTICE TO CONVENE an extraordinary general meeting of Nordic Shipholding A/S in liquidation Nordic Shipholding A/S in liquidation (CVR no. 76 35 17 16) (the “Company”) hereby convenes an extraordinary general meeting to be held on Thursday 28 December 2023, at 09.00 (CET) Gorrissen Federspiel, Axel Towers, Axeltorv 2, DK-1609 Copenhagen V Agenda: 1. Presentation of the liquidator’s report 2. Presentation of the final and audited liquidation accounts for adoption 3. Resolution on liquidation of the Company with final effect 4. Any other business Complete proposals Item 1 – Presentation of the liquidator’s report Item 2 – Presentation of the final and audited liquidation accounts for adoption The liquidator proposes to the general meeting to adopt the final and audited liquidation accounts. There will be no distribution of liquidation proceeds to the shareholders of the Company in connection with the liquidation. The final and audited liquidation accounts is available for review on the C
Selskabsmeddelelse 5/20236.12.2023 14:51:46 CET | pressemeddelelse
INDKALDELSE til ekstraordinær generalforsamling i Nordic Shipholding A/S i likvidation Nordic Shipholding A/S i likvidation, CVR-nr. 76 35 17 16 (”Selskabet”) indkalder herved til ekstraordinær generalforsamling, der afholdes Torsdag den 28. december 2023, kl. 09.00, Gorrissen Federspiel, Axel Towers, Axeltorv 2, 1609 København V. Dagsorden 1. Aflæggelse af likvidators beretning 2. Forelæggelse af endeligt og revideret likvidationsregnskab til godkendelse 3. Beslutning om endelig likvidation af Selskabet 4. Eventuelt Fuldstændige forslag Punkt 1 – Aflæggelse af likvidators beretning Punkt 2 – Forelæggelse af endeligt og revideret likvidationsregnskab til godkendelse Likvidator foreslår, at det endelige likvidationsregnskab godkendes. Der vil ikke være likvidationsprovenu til fordeling blandt Selskabets aktionærer i forbindelse med likvidationens gennemførelse. Det endelige likvidationsregnskab er tilgængeligt på Selskabets hjemmeside, www.nordicshipholding.com, og er vedlagt denne indk
“GigaFarm” capable of replacing 1% of UAE food imports set for construction in Dubai Food Tech Valley6.12.2023 14:42:59 CET | Press release
DUBAI, United Arab Emirates, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Food Tech Valley has signed an agreement at COP28 with ReFarmTM to start construction on a 900,000 sq. ft. game-changing “GigaFarm”. The innovative waste-to-value farm will be capable of recycling more than 50,000 tonnes of food waste and growing two billion plants each year. ReFarmTM was established in the UAE by SSK Enterprise and Christof Global Impact (CGI) as a group of companies with focus on projects with circularity and clean technologies. The brand chose vertical farming technology developed by infrastructure supplier Intelligent Growth Solutions (IGS) and is set to start construction in mid-2024 at Dubai’s Food Tech Valley, a master development launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum and being led by major Dubai property developer, Wasl. ReFarmTM has engaged its lead bank to arrange support from UK Export Finance within the UK Government’s Department for Business & Trade. In a global first,
Wolters Kluwer confirms position as a top ESG software provider by being named a Leader in Enterprise Carbon Management software6.12.2023 14:32:27 CET | Press release
PRESS RELEASE Wolters Kluwer confirms position as a top ESG software provider by being named a Leader in Enterprise Carbon Management software Independent research firm recognizes Wolters Kluwer’s Enablon as a Leader in Carbon Management software, with high scores in key data management categories. New York – December 6, 2023 – Independent research firm, Verdantix, has named Wolters Kluwer a Leader in Enterprise Carbon Management software in its Green Quadrant: Enterprise Carbon Management Software 2023 report. This report provides a comprehensive, fact-based comparison of the 19 most prominent enterprise carbon management software vendors in the market. The analysis is based on the proprietary Verdantix Green Quadrant methodology, which incorporated two-hour live briefings, desktop research, and vendor responses to a 70-point questionnaire covering 12 capability and six market-momentum categories. Wolters Kluwer, through its Enablon Vision platform, achieved high scores in the followi
Disclosure of transactions in the shares of Gabriel Holding A/S by persons discharging managerial responsibilities and closely related parties6.12.2023 14:22:32 CET | Press release
In accordance with Article 19 of the Market Abuse Regulation, Gabriel Holding A/S publishes the following transaction. Attachment Gabriel Holding AS - Announcement no 11 2023 - Managers and closely related parties' transactions